ERDAFITINIB
- Product Name
- ERDAFITINIB
- CAS No.
- 1346242-81-6
- Chemical Name
- ERDAFITINIB
- Synonyms
- JNJ-42756493;CS-2043;Erdafitinib;erdafitnnib;Suftalan Zine;Erdafitinib-d6;Erdafitinib(JNJ-42756493);JNJ-42756493 (Erdafitinib);5-amino-6-fluoropyridine-7-carbonitrile;ERDAFITINIB;JNJ-42756493 ;JNJ 42756493 ;JNJ42756493
- CBNumber
- CB42725628
- Molecular Formula
- C25H30N6O2
- Formula Weight
- 446.54
- MOL File
- 1346242-81-6.mol
ERDAFITINIB Property
- Melting point:
- 136-140°C
- Boiling point:
- 662.3±55.0 °C(Predicted)
- Density
- 1.20±0.1 g/cm3(Predicted)
- storage temp.
- -20°C Freezer, Under inert atmosphere
- solubility
- DMSO (Slightly), Methanol (Slightly)
- form
- Solid
- pka
- 9.45±0.29(Predicted)
- color
- Yellow
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H302Harmful if swallowed
H317May cause an allergic skin reaction
H318Causes serious eye damage
H361Suspected of damaging fertility or the unborn child
H372Causes damage to organs through prolonged or repeated exposure
H413May cause long lasting harmful effects to aquatic life
- Precautionary statements
-
P201Obtain special instructions before use.
P202Do not handle until all safety precautions have been read and understood.
P260Do not breathe dust/fume/gas/mist/vapours/spray.
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P272Contaminated work clothing should not be allowed out of the workplace.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P281Use personal protective equipment as required.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P308+P313IF exposed or concerned: Get medical advice/attention.
P310Immediately call a POISON CENTER or doctor/physician.
P314Get medical advice/attention if you feel unwell.
P321Specific treatment (see … on this label).
P330Rinse mouth.
P333+P313IF SKIN irritation or rash occurs: Get medical advice/attention.
P363Wash contaminated clothing before reuse.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- 21813
- Product name
- JNJ-42756493
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $31
- Updated
- 2024/03/01
- Product number
- 21813
- Product name
- JNJ-42756493
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $85
- Updated
- 2024/03/01
- Product number
- 21813
- Product name
- JNJ-42756493
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $138
- Updated
- 2024/03/01
- Product number
- 21813
- Product name
- JNJ-42756493
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $269
- Updated
- 2024/03/01
- Product number
- E594600
- Product name
- Erdafitinib
- Packaging
- 1mg
- Price
- $45
- Updated
- 2021/12/16
ERDAFITINIB Chemical Properties,Usage,Production
Description
Erdafitinib is an oral pan-FGFR (1-4) inhibitor with has demonstrated promising activity in patients with metastatic or unresectable UC and other histologies (eg, cholangiocarcinoma) with FGFR alterations. It is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.
History
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy.
Uses
Erdafitinib is a fibroblast growth factor receptor inhibitor.
brand name
Balversa
General Description
Class: receptor tyrosine kinase; Treatment: metastatic urothelial carcinoma; Other name: JNJ-4275693; Elimination half-life = 59 h; Protein binding = 99.8%
target
Primary targets: Pan-FGFR
ERDAFITINIB Preparation Products And Raw materials
Raw materials
Preparation Products
ERDAFITINIB Suppliers
- Tel
- --
- Fax
- --
- info@trc-canada.com
- Country
- Canada
- ProdList
- 6668
- Advantage
- 58
View Lastest Price from ERDAFITINIB manufacturers
- Product
- Erdafitinib(JNJ-42756493) 1346242-81-6
- Price
- US $1.00/g
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 10000
- Release date
- 2024-06-19
- Product
- Erdafitinib 1346242-81-6
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- More Than 99%
- Supply Ability
- 100kg/Month
- Release date
- 2024-10-14
- Product
- Erdafitinib 1346242-81-6
- Price
- US $0.00/kg
- Min. Order
- 0.001kg
- Purity
- 99%
- Supply Ability
- kg
- Release date
- 2024-06-07